Literature DB >> 27624956

Effectiveness of Prenatal Tetanus, Diphtheria, and Acellular Pertussis Vaccination on Pertussis Severity in Infants.

Kathleen Winter1,2, James D Cherry3, Kathleen Harriman1.   

Abstract

BACKGROUND: All US women are recommended to receive a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine at 27-36 weeks gestation during each pregnancy to reduce the risk of pertussis to their infants. The impact of this strategy on severity of disease among infected infants has not been evaluated.
METHODS: We use a retrospective cohort study design evaluating whether pertussis-infected infants born in 2011-2015 whose mothers received Tdap vaccine during pregnancy had less severe pertussis, resulting in a lower risk of hospitalization or intensive care unit admission compared with infants born to unvaccinated mothers.
RESULTS: Infected infants of vaccinated mothers were significantly less likely to be hospitalized and had significantly shorter hospital stays compared with infants born to unvaccinated mothers, after adjustment for chronological and gestational age and receipt of diphtheria and tetanus toxoids and acellular pertussis vaccine. Unadjusted and adjusted vaccine effectiveness for preventing hospitalization among infants with pertussis was 72% (95% confidence interval [CI], 49%-85%) and 58% (95% CI 15%-80%), respectively. No infants born to vaccinated mothers required intubation or died of pertussis.
CONCLUSIONS: Infants with pertussis whose mothers received Tdap during pregnancy had a significantly lower risk of hospitalization and intensive care unit admission and shorter hospital stays. Prenatal Tdap vaccination is a critical strategy for reducing the morbidity and mortality from pertussis.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Pertussis; Tdap; VE; prenatal; vaccination

Mesh:

Substances:

Year:  2016        PMID: 27624956     DOI: 10.1093/cid/ciw633

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

1.  Five-Year Follow-up of a Severe Case of Pertussis in Oregon, 2012.

Authors:  Juventila Liko; William J Koenig; Paul R Cieslak
Journal:  Public Health Rep       Date:  2019-09-30       Impact factor: 2.792

2.  Pertussis vaccination in pregnancy in Canada: a cost-utility analysis.

Authors:  Bahaa Abu-Raya; Doug Coyle; Julie A Bettinger; Wendy Vaudry; Scott A Halperin; Manish Sadarangani
Journal:  CMAJ Open       Date:  2020-10-19

3.  Trends in Infant Pertussis Hospitalizations in the United States, 2009-2017.

Authors:  Sheree L Boulet; Allison T Chamberlain; Hope H Biswas; Denise J Jamieson
Journal:  JAMA       Date:  2019-12-03       Impact factor: 56.272

Review 4.  Pertussis vaccines and protective immunity.

Authors:  Parul Kapil; Tod J Merkel
Journal:  Curr Opin Immunol       Date:  2019-05-09       Impact factor: 7.486

5.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

6.  Immunization Practices of U.S. Obstetrician/Gynecologists for Pregnant Patients.

Authors:  Sean T O'Leary; Laura E Riley; Megan C Lindley; Mandy A Allison; Lori A Crane; Laura P Hurley; Brenda L Beaty; Michaela Brtnikova; Margaret Collins; Alison P Albert; Allison K Fisher; Angela J Jiles; Allison Kempe
Journal:  Am J Prev Med       Date:  2017-12-13       Impact factor: 5.043

Review 7.  Transfer of maternal immunity and programming of the newborn immune system.

Authors:  Madeleine F Jennewein; Bahaa Abu-Raya; Yiwei Jiang; Galit Alter; Arnaud Marchant
Journal:  Semin Immunopathol       Date:  2017-10-02       Impact factor: 9.623

8.  Association Between Third-Trimester Tdap Immunization and Neonatal Pertussis Antibody Concentration.

Authors:  C Mary Healy; Marcia A Rench; Laurie S Swaim; E O'Brian Smith; Haleh Sangi-Haghpeykar; Marsenia H Mathis; Monte D Martin; Carol J Baker
Journal:  JAMA       Date:  2018-10-09       Impact factor: 56.272

9.  Maternal Vaccination With a Monocomponent Pertussis Toxoid Vaccine Is Sufficient to Protect Infants in a Baboon Model of Whooping Cough.

Authors:  Parul Kapil; James F Papin; Roman F Wolf; Lindsey I Zimmerman; Leslie D Wagner; Tod J Merkel
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 5.226

10.  A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants.

Authors:  Christine Elizabeth Jones; Anna Calvert; Jo Southern; Mary Matheson; Nick Andrews; Asma Khalil; Hannah Cuthbertson; Bassam Hallis; Anna England; Paul T Heath; Elizabeth Miller
Journal:  BMC Med       Date:  2021-06-08       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.